Phase I/II trial of AmpliPhage-001 in patients with cystic fibrosis-associated Pseudomonas aeruginosa infections

Trial Profile

Phase I/II trial of AmpliPhage-001 in patients with cystic fibrosis-associated Pseudomonas aeruginosa infections

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs AB PA01 (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions; First in man
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 04 Aug 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017, according to AmpliPhi Biosciences media release.
    • 04 Aug 2016 According to AmpliPhi Biosciences media release, the company anticipates initiating a Phase 1 clinical trial in 2017.
    • 12 Jun 2015 According to an AmpliPhi Biosciences media release, this trial is expected to being in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top